Cargando…

Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

BACKGROUND: Pegloticase is approved in the US for treatment of refractory chronic gout. Since chronic kidney disease (CKD) is common in these patients, we conducted a post-hoc analysis of 2 replicate phase 3 trials and the subsequent open-label extension study to determine the effects of pegloticase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yood, Robert A, Ottery, Faith D, Irish, William, Wolfson, Marsha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937145/ https://www.ncbi.nlm.nih.gov/pubmed/24447425 http://dx.doi.org/10.1186/1756-0500-7-54

Ejemplares similares

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
por: Lipsky, Peter E, et al.
Publicado: (2014)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses
por: Iqbal, Ahmar, et al.
Publicado: (2015)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials
por: Micca, Joseph L, et al.
Publicado: (2013)

The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials
por: Schulman, Gerald, et al.
Publicado: (2016)

Pegloticase Induced Hemolytic Anemia in a Patient With G6PD Deficiency
por: Adashek, Michael L., et al.
Publicado: (2018)

Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results
por: Kimura, Go, et al.
Publicado: (2017)

Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial “EPO in Burns”
por: Günter, Christina Irene, et al.
Publicado: (2022)

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study
por: Chen, Sarah K, et al.
Publicado: (2020)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial
por: Matsui, Kunihiko, et al.
Publicado: (2022)

Post Hoc Subgroup Analysis of the BCause Study Assessing the Effect of AbobotulinumtoxinA on Post-Stroke Shoulder Pain in Adults
por: Riberto, Marcelo, et al.
Publicado: (2022)

Formoterol as reliever medication in asthma: a post-hoc analysis of the subgroup of the RELIEF study in East Asia
por: Cheng, Qi Jian, et al.
Publicado: (2016)

Benefit with preventive noninvasive ventilation in subgroups of patients at high-risk for reintubation: a post hoc analysis
por: Hernández, Gonzalo, et al.
Publicado: (2022)

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series
por: Botson, John K., et al.
Publicado: (2022)

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
por: Arthur, Christopher, et al.
Publicado: (2015)

Effectiveness of Tiotropium/Olodaterol in the Real World: A Post Hoc Subgroup Analysis After the First Year of Use
por: Sato, Atsuyasu, et al.
Publicado: (2022)

TIP peptide inhalation in oleic acid-induced experimental lung injury: a post-hoc comparison
por: Hartmann, Erik K, et al.
Publicado: (2013)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Singh, Dave, et al.
Publicado: (2023)

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
por: Nirogi, Ramakrishna, et al.
Publicado: (2022)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6kjdhrv9m4bfpaba830tsrkb3q